Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.56 |
| ▸ | CTSS | P25774 | 4/20 | 0.56 |
| ▸ | CTSL | P07711 | 3/20 | 0.56 |
| ▸ | CTSB | P07858 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30581394 | 0.87 | CTSL (0.62) | CTSKCTSSCTSLCTSB | |
| SCHEMBL3644164 | 0.87 | CTSK (0.57) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL6456168 | 0.86 | CTSL (0.58) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL6456176 | 0.86 | CTSL (0.58) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL1170934 | 0.85 | CTSK (0.56) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL2509736 | 0.85 | CTSK (0.56) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL13150913 | 0.85 | CTSK (0.56) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL12196275 | 0.85 | CTSK (0.56) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL9434411 | 0.85 | CTSK (0.59) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL11049388 | 0.85 | CTSK (0.59) | CTSKCTSSCTSLCTSBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-6924397-B2 | Process for the preparation of α-chloroketones from alkyl esters | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| US-20050090670-A1 | PROCESS FOR THE PREPARATION OF ALPHA-CHLOROKETONES FROM ALKYL ESTERS | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090670-A1 | PROCESS FOR THE PREPARATION OF ALPHA-CHLOROKETONES FROM ALKYL ESTERS | KHK, BCKDK, STS | CTSK 39/4885CTSS 430/4885CTSL 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.